Networking, trends and innovation: these are the keywords that best represent Vitafoods Europe, the leading event in Europe dedicated to the nutraceutical industry. It is an appointment that each year attracts a global audience from all stages of the nutraceutical supply chain: from the sourcing of ingredients and raw materials to contract manufacturing, from services and equipment to the sale of finished products.
A must-attend event for industry professionals, made even more important by the significant growth observed in recent years for the nutraceutical market.
In fact, the dietary supplement industry is growing rapidly all over the world and Italy is no exception. In 2021, the value of the global market was 150 billion euros, with an annual increase of 4.7% over the last three years. Moreover, according to the data that emerged this February during the conference promoted by Integratori & Salute 'The supplement sector: reshaping the future', Italy ranks as the market leader in Europe in the supplement sector with 26% market share and ranks eighth as an exporter globally.
A development driven by numerous factors, including a growing interest on the part of consumers in maintaining the health and general well-being of their bodies and the desire to combat, but above all prevent, the onset of numerous chronic diseases.
This is well known by Biofarma Group, which for years has been active in the development and production of nutraceuticals, with the aim of providing products that represent a small daily gesture with an extraordinary impact: preventing diseases, improving health, delaying the ageing process and increasing life expectancy.
As a leading Italian CDMO player on the European nutraceutical market, the Biofarma Group will be attending Vitafoods Europe with an articulated proposal developed by our R&D team of more than 50 researchers that worked on multiple therapeutic targets including the metabolic area, gastro-intestinal wellbeing, well ageing, beauty from within and an organic supplements proposition. This latter target has undergone significant development thanks to Biofarma Group's recent acquisition of Nutraskills, one of the reference companies on the French CDMO market for nutraceuticals with a particular focus on biological and organic products.
Finally, special attention will be paid to clinically validated products that are products whose formulation and therapeutic effects are supported by clinical studies conducted by the Group thanks to the dense network of collaborations established with important research centres and universities. An example of this is the product Leaky Gut, a bi-layer seaweed-based tablet, clinically proven to promote the well-being of the intestinal tract and strengthen the immune system thanks to its ability to act as a true immunomodulator. As well as the product IBS 10 Multi Strain, indicated for reducing the symptoms of irritable bowel syndrome through the synergistic action of 10 different selected probiotic strains.
Our group looks forward to three days of engaging conversations, inspiration and networking with both new and existing partners and colleagues within the industry. Make sure to visit Biofarma Group booth B80 to learn more about Biofarma Group portfolio, in-house manufacturing capabilities and the science that supports our offerings.
